Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1995

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Progestational contraception. [La contraception progestative.]

AUTHORS

Cohen J

SOURCE

Contraception, Fertilite, Sexualite. 1995 Jul-Aug;23(7-8):442-4.

ABSTRACT

Indications for progestational contraception use include intolerance to estrogens, contraindications to estrogen use,

disorders predisposing to thromboses, renal insufficiency, benign breast disease, and high risk of developing breast

cancer. Progestational injectables available in France are Depo-Provera and Noristerat. Advantages of injectables

are their ease to administer, prolonged duration of action, and no risks associated with estrogens. Inconveniences

include changes in lipid and hydrocarbon metabolism and changes in menstrual bleeding (amenorrhea and

uninterrupted bleeding). Progestin-only oral contraceptives (OCs) consist of two types: continual administration of

low dose OCs and interrupted administration. Interrupted administration of progestin-only contraceptives is used

mainly in France. It should be reserved for women with contraindications to estrogen-progestogen contraception.

Women use these OCs during days 5-25 of the menstrual cycle. The contraceptive mode of action of continual

administration of low dose progestin-only OCs is changes in cervical mucus and of the endometrium. It does not

suppress ovulation. It should be reserved for women with hypertension, diabetes, hyperlipidemia and high vascular

risk, and nulliparous women with contraindications to the IUD. The failure rate for continual administration of low

dose progestin-only OCs is 1-3% (Pearl index). Progesterone-releasing IUDs lead to endometrial atrophy and are

thus ideal for women over 35 with menorrhagia or dysmenorrhea. Their duration of action is 18 months. Their failure

rate is 1.68% (Pearl index). The contraceptive implant system consisting of six 3-cm long capsules releases 20-50

mcg levonorgestrel/day for more than three years. A leading side effect is menstruation disorders, making it

sometimes difficult for women to accept. Its Pearl index is 0.3%. Vaginal rings releasing norgestrel and estradiol

are currently undergoing research. They are in situ for 21 days and removed to allow menstrual blood to flow. They

can be used for six cycles. (PubHealth.info Document ID: CONT2T 3023-06)

PubHealth.info NOTE: The author(s) of this article titled, "Progestational contraception. [La contraception

progestative.]", is(are) Cohen J. The source of this article is "Contraception, Fertilite, Sexualite. 1995 Jul-Aug;23(7-

8):442-4.". This article was published in 1995 in French language(s). (PubHealth.info® Document ID: CONT2T 3023-

06. All rights reserved with PubHealth.info) PIN: 8023

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.